TABLE 2.
EAE in Csf2−/− mice was enabled by an anti-CD25 mAb and reversed by an anti-CD4 mAb
| Figure | Strain | mAb pretreatment | Incidence | Means (±se) cumulative scores | P | Means (±se) maximal scores | P | % Maximal weight loss | P |
|---|---|---|---|---|---|---|---|---|---|
| 3A and B | Csf2−/− | No mAb | 1 of 6 | 4.3 ± 4.3 | * | 0.3 ± 0.3 | * | 4.0 ± 3.0% | * |
| 3A and B | Csf2−/− | Anti-IFN-γ | 7 of 8 | 8.6 ± 3.0 | ns | 1.0 ± 0.3 | ns | 7.8 ± 2.9% | ns |
| 3A and B | Csf2−/− | Anti-CD25 | 7 of 7 | 77.3 ± 10.0 | <0.001 | 3.6 ± 0.3 | <0.001 | 29.3 ± 2.0% | <0.001 |
| 3C and D | Csf2−/− | No mAb | 1 of 5 | 1.5 ± 1.5 | * | 0.1 ± 0.1 | * | 4.4 ± 2.2% | * |
| 3C and D | Csf2−/− | Y13 isotype control | 2 of 7 | 3.7 ± 2.4 | ns | 0.2 ± 0.1 | ns | 6.1 ± 1.7% | ns |
| 3C and D | Csf2−/− | Anti-CD25 | 9 of 9 | 82.3 ± 6.6 | <0.001 | 3.3 ± 0.2 | <0.001 | 21.8 ± 3.5% | 0.008 |
| 3C and D | Csf2−/− | Anti-CD25 + anti-CD8 | 9 of 9 | 80.1 ± 7.1 | <0.001 | 3.6 ± 0.2 | <0.001 | 17.6 ± 3.9% | ns |
| 3C and D | Csf2−/− | Anti-CD25 + anti-CD4 | 1 of 8 | 0.6 ± 0.6 | ns | 0.1 ± 0.1 | ns | 7.9 ± 2.5% | ns |
| 3E and F | C57BL/6 | Anti-CD25 + anti-CD8 | 6 of 6 | 124.8 ± 1.9 | <0.001 | 4.0 ± 0.0 | <0.001 | 32.0 ± 2.0% | <0.001 |
| 3E and F | C57BL/6 | Anti-CD25 + anti-CD4 | 2 of 5 | 2.7 ± 1.7 | ns | 0.5 ± 0.4 | ns | 5.7 ± 1.9% | ns |
These data are portrayed in Fig. 3A–F. (Fig. 3A and B) Designated mouse strains were injected i.p. with purified R4.6A2 anti-IFN-γ rat IgG1 or PC61 anti-CD25 rat IgG1 mAb on d −4 and −2. (Fig. 3C–F) Alternatively, mice were injected with PC61, Y13 (isotype control rat IgG1), GK1.5 (anti-CD4 rat IgG2b), and/or 53.6-7 (anti-CD8a rat IgG2a) mAb on d −5 and −3. All mAb were injected at a dose of 250 µg/injection. Mice were immunized on d 0 with 200 µg MOG35–55 in CFA with i.p. injections of Ptx on d 0 and 2. Mice were scored and weighed daily. Shown are the mean cumulative and maximal scores (±sem). ns, not significant; asterisk indicates control group.